United States: To Be Prepared Is Half The Victory

Last Updated: April 28 2016
Article by John M. Clerici

In the second in our series of alerts relating to drug pricing, we identify several considerations and potential actions that a pharmaceutical or biotechnology company can take to address the current headwinds impacting medical innovation at both the federal and state levels. The ultimate outcome of the 2016 elections―presidential, congressional and state―will have a tremendous impact upon any analysis of drug pricing concerns. However, several assumptions can be made, no matter the outcome, that a medical innovator can plan for now, even in advance of the election.

To begin, it is important to focus on the central drivers for the current discussions around drug pricing. In the simplest terms, the debate comes down to two primary concerns about current and projected drug prices: (1) their impact on the cost of health care, with a particular focus on Medicare and Medicaid; and (2) their impact on patients' access to drugs, and any limitations to that access created by pricing.

With respect to the first driver, policymakers at the federal and state level are acutely focused on "big ticket" products that have the potential to negatively affect the solvency of Medicaid and Medicare. The enormous benefit of breakthrough therapeutics that cure, not just treat, Hepatitis C have highlighted that the long-term positive pharmcoeconomic1 value of eliminating the need for liver transplants, and reducing deaths, does not always negate the short-term costs of expensive highly innovative products.

With respect to the second driver, access by patients, the ever-increasing role of patient advocates and patient-centered health care has created powerful grassroots pressure against prohibitively high drug costs, which may deny the most vulnerable populations fair access to life-saving medical innovations. Somewhat ironically, the same groups and forces are the ones pressuring policymakers―including the Food and Drug Administration (FDA)―to remove unnecessary barriers to innovation.

Importantly, neither of these key drivers will be affected by the outcome of the elections.

With this background in mind, we suggest medical innovators that bring to market life-saving therapeutics, vaccines, devices and diagnostics consider the following actions to ensure the current drug pricing debate, and potential ensuing policy changes, do not stifle innovation:

  1. Do your homework upfront before investment. Even with the issue of drug pricing front and center, innovators are not considering the impact of pricing early enough in the investment cycle. Historically, investors often took the view that, when it comes to medicine, if the product works and is approved by the FDA, the product will be "correctly" priced and reimbursed, yielding a reasonable return for investors.

    However, investors now include health outcome, performance, regulatory strategy and pricing as critical decision points when making an investment decision. They therefore need to understand who will pay for the product and how much they'll pay, regardless of whether the technology is a therapeutic, diagnostic or device. Early engagement with an expert in reimbursement and commercial pricing would serve all investors well, including those looking to invest in medicine early in development, to determine whether return on investment is realistic.
  2. Closely monitor and take a role in policy changes. As discussed in our last alert, the Obama administration and Congress, as well as governors and state legislatures, are under tremendous fiscal pressure to address drug pricing, due both to the first driver of cost and political pressure, and to the second driver of patient advocates/access. Extraordinary actions such as invoking federal "march-in" rights have been proposed. As we have noted, for the most part, these proposals have been rebuffed.

    However, without the voice of innovators being heard early and often, the industry as a whole is at grave risk. Significantly, these issues, such as the role of the Bayh-Dole Act, are heavily nuanced and rather complicated. Thus, it is essential to work with an expert in the relevant field, in order to ensure that the political and public relations positions taken by innovators are well grounded.
  3. Consider all implications before going to market. If an innovator has not considered all aspects of pricing early, including reimbursement and the impact upon federal programs, it is essential that all such considerations be analyzed concurrent with completing development of any medical product. Obviously, the economic analysis and business case issues familiar to any commercial entity prior to launch of a product are well known and often considered. However, the better-prepared innovators must take extra steps. These includes early engagement with patient advocates and consideration of the increasing role of a patient-centered, outcome-based private and public health care system.

    It is also critical to examine your footing to defend those positions administratively (through the regulatory process), legislatively (through the political process) and legally (through the courts). All three of these pillars must be thoroughly analyzed and considered, of course along with a traditional marketing and public relations strategy. Given that the issue of drug pricing is at the forefront of the minds of federal and state policymakers, ensuring an early and comprehensive analysis of your actions, and of the likely reactions by regulators, lawmakers and the courts, is key to success.

Dentons and Tiber Creek Partners are available to discuss all aspects of developing a proactive, well-founded drug pricing strategy at any point in the process. Our next advisory on this topic will focus on the development of a reimbursement strategy, which of necessity includes pricing.2

Footnotes

1 Pharmacoeconomics has been defined as the description and analysis of the cost of drug therapy to health care systems and society. More specifically, pharmacoeconomic research is the process of identifying, measuring and comparing the costs, risks and benefits of programs, services or therapies and determining which alternative produces the best health outcome for the resource invested.

2 As an update to the first of these alerts, in which we pointed out that the exercise of retained rights was not a closed issue, on March 28, 2016, a group of House and Senate Democrats asked the National Institutes of Health (NIH) to hold a public hearing to explore whether the NIH's criteria for imposing "march-in authority" to stem drug prices would be met in the case of the cancer drug Xtandi. The letter states: "An open and transparent public hearing on Xtandi by the NIH would help to provide insight into NIH's decision-making process on this case. In addition, we think that a public hearing is important to allow the public to engage in a dialogue with the Department of Health and Human Services and NIH in order to better understand its position on the use of march-in to address excessive prices."

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
24 Oct 2017, Seminar, Washington, DC, United States

The Dentons Forum for Women Executives invites you to join us for a luncheon featuring guest speaker Liza Mundy, journalist and author. Ms. Mundy recently released her latest book, Code Girls, the riveting untold story of more than 10,000 spirited young American women who cracked German and Japanese codes to help win World War II.

27 Oct 2017, Seminar, New York, United States

Please join us for a milestone event, our 10th annual CLE Seminar for In-House Counsel.

1 Nov 2017, Seminar, Washington, DC, United States

Celebrate the 58th anniversary of Dentons' Government Contracts practice

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.